Imperial Confidence in Concept: ICiC

Lead Research Organisation: Imperial College London
Department Name: UNLISTED

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding.  It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

People

ORCID iD

Publications

10 25 50

publication icon
Chronopoulos A (2017) Exosomes as a platform for 'liquid biopsy' in pancreatic cancer in Convergent Science Physical Oncology

publication icon
Goya Grocin A (2019) Whole Proteome Profiling of N-Myristoyltransferase Activity and Inhibition Using Sortase A. in Molecular & cellular proteomics : MCP

publication icon
Larrouy-Maumus G (2019) Lipids as Biomarkers of Cancer and Bacterial Infections. in Current medicinal chemistry

publication icon
McCrae C (2018) Lanosterol Synthase Regulates Human Rhinovirus Replication in Human Bronchial Epithelial Cells. in American journal of respiratory cell and molecular biology

publication icon
Moser N (2018) A Scalable ISFET Sensing and Memory Array With Sensor Auto-Calibration for On-Chip Real-Time DNA Detection. in IEEE transactions on biomedical circuits and systems

publication icon
Samandari M (2018) Liquid biopsies for management of pancreatic cancer. in Translational research : the journal of laboratory and clinical medicine

 
Description STEM for Britain 2017
Geographic Reach Europe 
Policy Influence Type Influenced training of practitioners or researchers
Impact Although there is no immediate change in any health policy, the research presented in the House of Commons by Antonios Chronopoulos entails the development of low-cost, portable microfluidic chips that leverage cutting-edge acoustic-based microfluidic technology and nanomaterials for non-invasive (blood-based) early detection of pancreatic cancer, thus obviating the need for invasive tissue biopsies.
 
Description (ExoSonic) - A microfluidic chip for non-invasive, early detection of pancreatic cancer - liquid biopsy
Amount € 149,997 (EUR)
Funding ID 780360 
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 02/2018 
End 07/2019
 
Description Confidence in Concept
Amount £840,000 (GBP)
Funding ID MC_PC_16046 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2017 
End 02/2019
 
Description Confidence in Concept
Amount £944,000 (GBP)
Funding ID MC_PC_17162 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2018 
End 02/2020
 
Description Doctoral training centre in Neurotechnology
Amount £0 (GBP)
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 10/2017 
End 09/2021
 
Description ICiC 4 - Baldwin - Innovate UK Investment accelerator
Amount £149,475 (GBP)
Funding ID 582222 
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 01/2018 
End 12/2018
 
Description ICiC 4 - Choi - Bioengineering-Industry funding scheme Studentship
Amount £50,000 (GBP)
Organisation Bracco Group 
Sector Private
Country Italy
Start 01/2019 
End 12/2021
 
Description ICiC 4 - Choi - Imperial-ICR Cancer Research UK Centre of Excellence
Amount £165,000 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2018 
End 09/2022
 
Description ICiC 4 - Choi - The Cure Starts Now
Amount $100,496 (USD)
Organisation The Cure Starts Now 
Sector Charity/Non Profit
Country United States
Start 01/2019 
End 12/2019
 
Description ICiC 4 - Choi - The Republic of Turkey Ministry of National Education PhD Studentship
Amount £165,000 (GBP)
Organisation Government of Turkey 
Department Ministry of National Education
Sector Public
Country Turkey
Start 01/2019 
End 12/2021
 
Description ICiC 4 - Griesenbach - GM-CSF gene therapy for pulmonary alveolar proteinosis
Amount £74,924 (GBP)
Funding ID RSRO_P62528 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 09/2017 
End 06/2018
 
Description ICiC 4 - Isalan - Imperial Confidence in Concept Scheme
Amount £79,057 (GBP)
Organisation Imperial College London 
Sector Academic/University
Country United Kingdom
Start 09/2018 
End 08/2019
 
Description ICiC 4 - Mylonas - MedCaP: MedTech Catalyst Programme
Amount $1,400,000 (SGD)
Organisation Agency for Science, Technology and Research (A*STAR) 
Sector Public
Country Singapore
Start 04/2020 
End 10/2021
 
Description ICiC 4 - Shattock - Vaccines for Global Development
Amount £1,999,713 (GBP)
Funding ID 971617 
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 10/2018 
End 09/2020
 
Description ICiC 4 - Terzidou - March of Dimes Prematurity Research Center
Amount £368,247 (GBP)
Organisation March of Dimes Foundation 
Sector Charity/Non Profit
Country United States
Start 04/2019 
End 04/2021
 
Description ICiC 4 - Weinberg - Project Grant
Amount £177,823 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2019 
End 07/2020
 
Description ICiC 4 - Wigneshweraraj - Leverhulme Trust - Project Grant
Amount £200,000 (GBP)
Organisation The Leverhulme Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2018 
End 07/2021
 
Description ICiC 4_Zhao_Small and large molecule inhibitors of ZIP12
Amount £4,400,000 (GBP)
Organisation Apollo Therapeutics 
Sector Private
Country United Kingdom
Start 05/2019 
End 04/2021
 
Description Innovate UK Investment Accelerator
Amount £149,475 (GBP)
Funding ID 582222 
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 01/2018 
End 12/2018
 
Description Project Grant
Amount £200,000 (GBP)
Organisation The Leverhulme Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2018 
 
Description Research Fellowship Grant 2016 - MT
Amount £56,600 (GBP)
Funding ID RF16\100015 
Organisation Imperial College Healthcare NHS Trust 
Department Imperial College Healthcare NHS Charity
Sector Charity/Non Profit
Country United Kingdom
Start 07/2016 
End 07/2017
 
Description Research Fellowship Grant 2017 - EW
Amount £50,000 (GBP)
Funding ID RF17/1011 
Organisation Imperial College Healthcare NHS Trust 
Department Imperial College Healthcare NHS Charity
Sector Charity/Non Profit
Country United Kingdom
Start 09/2017 
End 07/2018
 
Description Research Project Grant
Amount £29,500 (GBP)
Organisation Genesis Research Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2018 
End 07/2018
 
Description Ultrasound delivery of BACE1 inhibitors across the blood-brain barrier in a model of Alzheimer's disease
Amount £249,203 (GBP)
Funding ID ARUK-IRG2017A-7 
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2017 
End 10/2020
 
Title Isalan - ICiC 4 - ZF-HD 
Description Huntington's disease (HD) is a lethal inherited neurodegenerative disorder which currently has no cure. It belongs to a class of rare diseases, including spinocerebral ataxias, caused by expansions of CAG-repeat sequences within genes. We have developed a gene therapy approach, based on reducing the levels of the HD gene products, while maintaining the levels of the normal proteins. By designing a zinc finger protein (transcription factor repressor) to bind expanded CAG-repeats, we were the first to demonstrate efficient mutant Huntingtin (HTT) repression in mice, with a single treatment eliminating HD clasping symptoms for several weeks (Synthetic zinc finger repressors reduce mutant Huntingtin expression in the brains of R6/2 mice. PNAS 109: E3136-E3145, 2012). The original treatment only lasted a couple of weeks, but we have spent the last five years working on second and third generation constructs to allow sustained repression of mutant Huntingtin, in the whole brain (up to 80% lowering after AAV injection). We have recently published a new paper on this work, reporting how we can now achieve specific repression of mutant Huntingtin for a least six months (and maybe longer) after a single treatment (Agustín-Pavón et al. Mol. Neurodegeneration 11(1):64, 2016). 
Type Of Material Biological samples 
Year Produced 2016 
Provided To Others? Yes  
Impact This has the potential to repress the molecular cause Huntington's disease in humans with infrequent dosing and no mutagenic genome cutting (unlike other treatments in development). 
URL https://doi.org/10.1186/s13024-016-0128-x
 
Title Solari - ICiC4 - Novel Protein Kinase D Inhibitors 
Description We have chemically synthesised a number of novel protein kinase D inhibitors attempting to enhance cellular potency by targeting a Cys residue in the active site of the kinase. 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact The new compounds are still being validated and tested in biological systems. 
 
Description Blagborough - ICiC4 - Institut de Recherche en Sciences de la Santé, Burkina Faso 
Organisation National Center for Scientific and Technological Research (CNRST)
Department Institute of Research in Health Sciences
Country Burkina Faso 
Sector Public 
PI Contribution Design of and generation of materials to assess a Novel Whole-Parasite Anti-Malarial vaccine in the field.
Collaborator Contribution Assessment of transmission-blocking capabilities of a Novel Whole-Parasite Anti-Malarial vaccine in the field by direct-membrane feeding assay (DMFA) on P. falciparum.
Impact N/A
Start Year 2016
 
Description Development of graphene based biosensor for exosome analysis 
Organisation Imperial College London
Department Institute of Clinical Sciences
Country United Kingdom 
Sector Academic/University 
PI Contribution Providing biologicals (antibodies, exosomes) to be tested with the biosensor. Sample preparation and electron microscopy imaging of sensors. Microfluidic devices to integrate with sensor.Prototyping to increase device usability
Collaborator Contribution Graphene sensor fabrication Electronic equipment to analyse sensor output Surface analysis (XPS)
Impact Multidisciplinary: Involving the field of biotechnology (microfluidic chip), physics (separation of particules using acoustic waves) and materials (use of graphene-based detection of exosomes)
Start Year 2016
 
Description Edwards - ICiC 4 - AA 
Organisation Imperial College London
Department Department of Chemistry
Country United Kingdom 
Sector Academic/University 
PI Contribution None
Collaborator Contribution Provided reagents
Impact None yet
Start Year 2017
 
Description Edwards - ICiC 4 - JS 
Organisation University of Bristol
Country United Kingdom 
Sector Academic/University 
PI Contribution Dr Edwards is an expert in antibiotic resistance and leads the project at Imperial
Collaborator Contribution Provided recombinant proteins, plasmids and strains
Impact None yet
Start Year 2017
 
Description Griesenbach - ICiC4 - Dr Cliff Morgan 
Organisation Royal Brompton & Harefield NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution Expertise in pulmonary gene transfer and vector design.
Collaborator Contribution Disease expert
Impact N/A
Start Year 2016
 
Description ICiC 4 - Terzidou - Bed-side miRNA analysis to predict preterm birth 
Organisation Imperial College London
Department Department of Bioengineering
Country United Kingdom 
Sector Academic/University 
PI Contribution Identified miRNA markers that can predict preterm birth/cervical shortening in high risk women which can be applied to test the paper-based assay developed by Dr Ladame. Providing biologically relevant samples for large validation using low risk population.
Collaborator Contribution Development of a bed-side test based on Dr Ladame's paper-based assay to detect our identified miRNA markers.
Impact https://doi.org/10.1039/C9CC05607F
Start Year 2018
 
Description Kyrgiou - ICiC 4 - Systematic review on impact of margins 
Organisation European Federation For Colposcopy
Country Belgium 
Sector Charity/Non Profit 
PI Contribution Scientific contribution the published paper Arbyn Lancet Oncol 2017
Collaborator Contribution Scientific contribution to the research and writing of the paper
Impact M Arbyn, CWE Redman, F Verdoodt, M Kyrgiou, M Tzafettas, S Ghaem-Maghami, KU Petry, S Leeson, C Bergeron, P Nieminen, J Gondry, O Reich, EL Moss. Incomplete excision of cervical precancer as predictor of treatment failure: a systematic review and meta-analysis. Lancet Oncology 2017
Start Year 2016
 
Description Porter - ICiC4 - CRUK centre collaboration 
Organisation Cancer Research UK
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Alexandra Porter is a member of the CRUK centre. As such she is invited to events and to apply to funding calls from the centre, including studentships, fellowships pump prime funding. She attends meetings held by the CRUK centre at which she participates in brain storming sessions to come up with new research directions.
Collaborator Contribution They organise the meetings and provide funding through the centre.
Impact N/A
Start Year 2017
 
Description Wigneshweraraj - ICiC4 - Dr Luiz de Carvahlo, Crick Institute 
Organisation Francis Crick Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution We conceptualised the research idea.
Collaborator Contribution Provided metablome data.
Impact We have obtained substantial preliminary data.
Start Year 2016
 
Description Wigneshweraraj - ICiC4 - Prof Boris Macek, University of Tubingen 
Organisation Eberhard Karls University of Tübingen
Country Germany 
Sector Academic/University 
PI Contribution We conceptualised the research idea.
Collaborator Contribution Provided proteomics data.
Impact We have obtained substantial preliminary data.
Start Year 2016
 
Title COMPOUNDS AND THEIR USE AS INHIBITORS OF N-MYRISTOYL TRANSFERASE 
Description This invention provides compounds of formula (I) and salts thereof, which have activity as inhibitors of N-myristoyl transferase (NMT). The invention also relates to uses of such compounds as medicaments, in particular in the treatment of a disease or disorder in which inhibition of N-myristoyl transferase provides a therapeutic or prophylactic effect, including protozoan infections (such as malaria and leishmaniasis), viral infections (such as human rhinovirus and HIV), and hyperproliferative disorders (such as B-cell lymphoma). 
IP Reference WO2017001812 
Protection Patent application published
Year Protection Granted 2017
Licensed Commercial In Confidence
Impact N/A
 
Title METHOD FOR PREDICTING CERVICAL SHORTENING AND PRETERM BIRTH 
Description The present invention provides method for predicting risk of cervical shortening, methods for predicting risk of preterm labour (PTL), and methods for characterising a pregnant subject having a history of previous PTL, mid-trimester loss or cervical cone biopsy as being in need of surveillance and/or intervention to prevent preterm labour, comprising determining the expression level of one or more of the miRNA molecules identified in Table 1 or Table 2 extracted from a biological sample obtained from said subject and comparing to a control value. Biochips and kits for use in carrying out the methods of the invention are also provided. 
IP Reference WO2016142688 
Protection Patent application published
Year Protection Granted 2016
Licensed No
Impact N/A
 
Title METHOD OF DETECTION 
Description The present invention is directed to a method for detecting the presence or absence of a bacterium resistant to a cyclic cationic polypeptide antibiotic, comprising: (a) subjecting a test sample to mass spectrometry analysis and generating a mass spectrum output; wherein said test sample comprises a bacterial membrane or a fragment thereof, wherein the fragment comprises a non- Lipid A component; (b) identifying in said mass spectrum output a first defined peak indicative of the presence of Lipid A modified by phosphoethanolamine, wherein said first defined peak is a peak present in a mass spectrum output for Lipid A modified by phosphoethanolamine and wherein said first defined peak is absent from a corresponding mass spectrum output for native Lipid A; and (c) wherein the presence of said first defined peak indicates the presence of a bacterium resistant to a cyclic cationic polypeptide antibiotic, and wherein the absence of said first defined peak indicates the absence of a bacterium resistant to a cyclic cationic polypeptide antibiotic. This method is also used in a screening method to identify an inhibitor of cyclic cationic polypeptide antibiotic resistance in a bacterium. The matrix solution can contain 2,5-dihydroxybenzoic acid and aids in the selective extraction, co-crystallisation and ionisation of native Lipid A and/or modified Lipid A as an integral part of a bacterial membrane. 
IP Reference WO2018158573 
Protection Patent application published
Year Protection Granted 2018
Licensed No
Impact N/A
 
Title NUCLEIC ACIDS, PEPTIDES AND METHODS 
Description Disclosed herein are novel nucleic acid molecules which encode novel polypeptides for use in treating polyglutamine diseases such as Huntington's disease. The polypeptides of the invention exhibit reduced immunotoxity in vivoand may have utility in sustained (mid-or long-term) expression in vivo. Also disclosed are methods for the treatment of polyglutamine diseases, such as Huntington's disease and the use of nucleic acids and polypeptides of the invention in medical therapy. Gene therapy methods and compositions, such as AAV vectors for use in gene therapy methods are also disclosed. 
IP Reference WO2017077329 
Protection Patent application published
Year Protection Granted 2017
Licensed Commercial In Confidence
Impact We are developing the technology to enter clinical trials.
 
Title PEPTIDES AND USES 
Description Disclosed herein are zinc finger peptides having at least 4 zinc finger domains, such as 6, 11, 12 or 18 zinc finger domains. The zinc finger peptides may be fused to effector domains for modulating gene expression. Zinc finger peptides of the invention are useful for targeting trinucleotide-repeat sequences in mutant genes and may have applications in gene therapy. The zinc finger peptides may have nucleic acid recognition sequences according to SEQ ID NO: 101. Also disclosed are methods for constructing poly-zinc finger peptides having arrays of at least 8 zinc finger domains, along with zinc finger frameworks that may be useful for selecting zinc finger peptides from libraries. 
IP Reference WO2012049332 
Protection Patent granted
Year Protection Granted 2012
Licensed Commercial In Confidence
Impact We are developing the technology to enter clinical trials.
 
Title SURGICAL DEVICE AND METHODS 
Description A surgical device (21) comprising a deployable peripheral structure (23) for insertion into a human or animal body, and one or more surgical tools (30) disposed at least partially within the deployable peripheral structure and having a plurality of tendons (24, 25, 26, 27) connected thereto operable to manipulate the or each surgical tool. 
IP Reference WO2015036753 
Protection Patent application published
Year Protection Granted 2015
Licensed No
Impact This is an enabling and potentially disrupting technology in the areas of minimally and ultra-minimally invasive surgery. Currently undergoing pre-clinical in vivo validation
 
Title Blagborough - ICiC4 - A Whole-Parasite Anti-Malarial Transmission-Blocking Vaccine 
Description We have developed a safe, cheap, and easily cultured transgenic rodent-malaria parasite which expresses a clinically-relevant human TBV antigen on its surface in native confirmation. Vaccination with these parasites produces an immune response against the native target with no cross-reactivity, and induces a potent transmission-blocking response. We have assessed the induced efficacy with a range of adjuvants/delivery systems/regimes using a variety of assays in both the lab and the field. Efficacy is favourable compared with other clinical TBVs under development. Our principle source of funding is an Imperial CiC award. 
Type Therapeutic Intervention - Vaccines
Current Stage Of Development Initial development
Year Development Stage Completed 2017
Development Status Actively seeking support
Impact N/A 
 
Description Edwards - ICiC 4 - Impfest 2016/17 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact 500 members of the public visited the 'superbugs zone' as part of Imperial festival. During this event I highlighted our work on this project.
Year(s) Of Engagement Activity 2016,2017
 
Description Edwards - ICiC 4 - TV Interviews 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact Gave TV interviews, either in the lab (ITV, Phoenix TV) or live in the studio (BBC world news) on the general issues of AMR and to highlight this project.
Year(s) Of Engagement Activity 2010,2017
 
Description ICiC 4 - Blagborough - Cambridge Science Festival 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Hundreds of individuals from a wide audience participated in evenst to learn about our research, which sparked questions and discussion afterwards, and the school reported increased interest in related subject areas.
Year(s) Of Engagement Activity 2016,2017,2018
 
Description ICiC 4 - Blagborough - Imperial Festival 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Hundreds of individuals from a wide audience participated in evenst to learn about our research, which sparked questions and discussion afterwards, and the school reported increased interest in related subject areas.
Year(s) Of Engagement Activity 2016,2017,2018
 
Description ICiC 4 - Blagborough - event at All Party Parliamentary Group 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact Hundreds of individuals from a wide audience participated in events to learn about our research, which sparked questions and discussion afterwards, and the school reported increased interest in related subject areas.
Year(s) Of Engagement Activity 2016,2017,2018
 
Description ICiC 4 - Weinberg - Presentation to entrepreneurs 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact Obtaining feedback on a "pitch" from industry specialists
Year(s) Of Engagement Activity 2018
 
Description Imperial festival 2016 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact Imperial Festival is the College's flagship annual science outreach event celebrating the best science, engineering and creativity from Imperial. With hundreds of attractions, demonstrations, interactive exhibits, talks, tours, workshops and performances put on by more than 500 exhibitors from the College's academic and student community, the 2016 Imperial Festival attracted more than 15,000 visitors to the College. The CMBL group presented some of the cutting edge bioengineering research on the topic acoustic-based microfluidic devices for early cancer diagnostics and how simple blood tests will soon replace invasive tissue biopsies for early-stage detection of certain aggressive cancers, such as pancreatic cancer. The CMBL exhibition at the Festival was a tremendous success attracting well over 600 visitors over the weekend, from the very young to the old, children, families, science enthusiasts, academics and even investors and funding bodies. The feedback we received after the event has been overwhelmingly positive.
Year(s) Of Engagement Activity 2014,2016
 
Description Isalan - ICiC4 - Huffington Post 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This was an online news article based on the paper:

Agustín-Pavón C, Mielcarek M, Garriga-Canut M & Isalan M. Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice. Molecular Neurodegeneration 11(1):64 (Sep. 2016).
Year(s) Of Engagement Activity 2016
URL http://www.huffingtonpost.co.uk/entry/a-single-injection-of-a-new-treatment-has-halted-progress-of-h...
 
Description Isalan - ICiC4 - La Vanguardia 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Spanish newspaper coverage (print/online) of the paper:

Agustín-Pavón C, Mielcarek M, Garriga-Canut M & Isalan M. Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice. Molecular Neurodegeneration 11(1):64 (Sep. 2016).
Year(s) Of Engagement Activity 2016
URL http://www.lavanguardia.com/vida/20160920/41451928214/una-inyeccion-reduce-enfermedad-de-huntington-...
 
Description Isalan - ICiC4 - Press release & general web blogs interest 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact After our press release our work has been picked up by many news agencies and has resulted in ongoing contacts with pharma and venture capitalists to find a route to translation.
Year(s) Of Engagement Activity 2016
URL http://www3.imperial.ac.uk/newsandeventspggrp/imperialcollege/newssummary/news_9-9-2016-13-13-26
 
Description Isalan - ICiC4 - Public Library of Science 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Online interview with PloS (Public Library of Science) which mentions this research on Huntington's disease.
Year(s) Of Engagement Activity 2017
URL http://blogs.plos.org/everyone/2017/02/09/interview-with-plos-one-academic-editor-mark-isalan/
 
Description Isalan - ICiC4 - Research *eu magazine interview 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact They interviewed Mark Isalan regarding the paper: Agustín-Pavón C, Mielcarek M, Garriga-Canut M & Isalan M. Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice. Molecular Neurodegeneration 11(1):64 (Sep. 2016). This resulted in a print/online magazine article.
Year(s) Of Engagement Activity 2016
URL http://cordis.europa.eu/news/rcn/126205_en.html
 
Description Kedgley - ICiC 4 - Imperial Festival 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact 400 people visited a stand at the Imperial Festival where we ran an activity stand and live experiment for people to try strength and dexterity tests and experience what how these change as people get older and develop conditions such as osteoarthritis.
Year(s) Of Engagement Activity 2017
 
Description Kedgley - ICiC 4 - Summer School 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Schools
Results and Impact 60 students attended the Year 9 Engineering Summer School, which created interest in the different ways in which engineering could be used in medicine.
Year(s) Of Engagement Activity 2017
 
Description Kedgley - ICiC4 - Imperial College Human Factors Interest Group 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Seminar presentation by Angela Kedgley, Imperial College Human Factors Interest Group (Nov 2016).

To link with other researchers and students in human factors to discuss key questions regarding how design affects patient concordance, monitoring, and compliance.
Year(s) Of Engagement Activity 2016
 
Description Kedgley - ICiC4 - Women@Imperial Week 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Schools
Results and Impact 30 students and 2 teachers attended as part of the 2017 Demo lecture programme for schools, which has the aim of getting girls interested in Physics and Engineering. There were many questions from the students, including requests for further information about the programme, internships and careers in the field.
Year(s) Of Engagement Activity 2017
 
Description Kyrgiou - ICiC 4 - ESGO 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Europe's landmark meeting in Gynaecological Oncology, offers professionals a unique opportunity to learn and discuss the latest medical and scientific developments in gynaecological cancers.
Year(s) Of Engagement Activity 2017
URL https://congress.esgo.org/
 
Description Kyrgiou - ICiC 4 - Eurogin 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact For thirty yearsThe Netherlands have been at the forefront of research on HPV and associated cancers. Among the pioneers in HPV research, the very dynamic Dutch teams have made major and continuing scientific contributions to early detection, prevention and basic research. It is also one of the first countries in the world that has implemented a comprehensive national HPV screening program. The robust scientific evidence provided by these teams confirms the cost effectiveness of risk-based screening and paves the way for the development of new strategies for the prevention of HPV-induced cancers. We are proud to highlight this scientific vitality and to pay tribute to this historic turning point which they brought.
Year(s) Of Engagement Activity 2017
URL http://www.eurogin.com/2017/
 
Description Kyrgiou - ICiC 4 - Reproductive Morbidity 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Undergraduate students
Results and Impact Organized by the Finnish Colposcopy Society and EFC. The Helsinki Advanced Colposcpopy Course has the BSCCP accreditation. Participants can get points for the colposcopy re-certification in UK and other countries (check the description of your national society).
Year(s) Of Engagement Activity 2018
URL http://efcolposcopy.eu/wp-content/uploads/2017/06/EFC-Nordic-Baltic-Advanced-Course-2018-advertiseme...
 
Description Kyrgiou - ICiC 4 - The Use of Innovative Spectroscopy 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact There was great scieintific interest and exchange of ideas following each of the events
Year(s) Of Engagement Activity 2018
 
Description Larrouy-Maumus - ICiC4 - Imperial Festival/Super Bug Zone 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact As part of the CMBI's outreach activities, we helped organising a few stands in the Superbug zone of the Imperial open to general public for awareness on AMR.
Year(s) Of Engagement Activity 2015,2016
 
Description Levin - ICiC 4 - IEEE 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact We have had multiple talks by members of our group at educational meeting
Year(s) Of Engagement Activity 2017
URL http://iscas2017.org/
 
Description Mylonas - ICiC4 - B.E.S.T. Innovation Symposium (IRCAD, IhU, France) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Presentation of our concept at the B.E.S.T. Innovation Symposium, IRCAD, IhU in Strasburg, France (Aug 2016). Industry and postgraduate students attended from around the world. Interesting discussions followed, including valuable input from the industry perspective. The novelty of the approach was acknowledged.
Year(s) Of Engagement Activity 2016
URL http://www.best-innovation.eu/best-innovation-symposium-2016/
 
Description Solari - ICiC4 - Research Seminar at AstraZeneca in Mollndal, Sweden 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Roberto Solari gave a research seminar describing work conducted in his lab to the respiratory research groups at AstraZeneca in Sweden.
Year(s) Of Engagement Activity 2017
 
Description Tate - ICiC2 & ICiC4 - CRUK lab tours, Imperial Festival 2016 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact This event made us appreciate the importance of public engagement and we had positive feedback from attendees.
Year(s) Of Engagement Activity 2016
URL https://www.imperial.ac.uk/festival/about/festival-2016/